Citi analyst David Lebowitz reiterated a Buy rating and $38.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)The analyst comments "This ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE